A Phase II Study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours.
Fazio, N Buzzoni, R Baudin, E Antonuzzo, L Hubner, Richard A Lahner, H De Herder, W Raderer, M Teulé, A Capdevila, J
Fazio, N
Buzzoni, R
Baudin, E
Antonuzzo, L
Hubner, Richard A
Lahner, H
De Herder, W
Raderer, M
Teulé, A
Capdevila, J
Citations
Altmetric:
Abstract
This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimus-resistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436).
Affiliation
Description
Date
2016-02
Publisher
Collections
Keywords
Type
Article
Citation
A Phase II Study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours. 2016, 36 (2):713-9 Anticancer Res